Amryt Pharma (Amryt Pharma) Gross Margin % : 44.86% (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Amryt Pharma's Gross Profit for the three months ended in Sep. 2022 was $27.4 Mil. Amryt Pharma's Revenue for the three months ended in Sep. 2022 was $61.1 Mil. Therefore, Amryt Pharma's Gross Margin % for the quarter that ended in Sep. 2022 was 44.86%.

Warning Sign:

Amryt Pharma PLC gross margin has been in long-term decline. The average rate of decline per year is -7.1%.

The historical rank and industry rank for Amryt Pharma's Gross Margin % or its related term are showing as below:

AMYT' s Gross Margin % Range Over the Past 10 Years
Min: 33.36 Med: 54.49 Max: 63.35
Current: 47.86

During the past 12 years, the highest Gross Margin % of Amryt Pharma was 63.35%. The lowest was 33.36%. And the median was 54.49%.

AMYT's Gross Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 46.405 vs AMYT: 47.86

Amryt Pharma had a gross margin of 44.86% for the quarter that ended in Sep. 2022 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Amryt Pharma was -7.10% per year.

Amryt Pharma Gross Margin % Historical Data

The historical data trend for Amryt Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Gross Margin % Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Gross Margin %

Get a 7-Day Free Trial

57.95

63.35

33.36

34.82

52.32

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Gross Margin %	Get a 7-Day Free Trial															51.76	46.77	47.95	51.32	44.86

Competitive Comparison of Amryt Pharma's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amryt Pharma's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Gross Margin % falls into.

Amryt Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Amryt Pharma's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )	=	Gross Profit (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	116.4	/	222.543
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(222.543 - 106.119)	/	222.543
	=	52.32 %

Amryt Pharma's Gross Margin for the quarter that ended in Sep. 2022 is calculated as

Gross Margin % (Q: Sep. 2022 )	=	Gross Profit (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	27.4	/	61.126
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(61.126 - 33.703)	/	61.126
	=	44.86 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Amryt Pharma (NAS:AMYT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Amryt Pharma had a gross margin of 44.86% for the quarter that ended in Sep. 2022 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Amryt Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).